Timing of changes in Alzheimer’s disease plasma biomarkers as assessed by amyloid and tau PET clocks

Abstract excerpt

Plasma biomarkers for Alzheimer’s disease (AD) are increasingly being used to assist in making an etiological diagnosis for cognitively impaired (CI) individuals or to identify cognitively unimpaired (CU) individuals with AD pathology who may be eligible for prevention trials. However, a better understanding of the timing of plasma biomarker changes is needed to optimize their use in clinical and research settings...

Topics

Open a Topic to create a Post that cites this publication.

• Amyloid beta-Peptides
• Amyloid beta-Protein Precursor
• Cognition
• Longitudinal Studies
• Peptide Fragments
• Presenilin-1
• Presenilin-2
• tau Proteins

Identifiers and source

Literature Corpus work

4c701bc0-0389-5de3-89a9-791eacf925bf

DOI

10.1101/2024.10.25.24316144